Skip to main content
HYUNDAI PHARMACEUTICAL CO., LTD logo

HYUNDAI PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 004310 ISIN · KR7004310009 KO Manufacturing
Open in API
Filings indexed 184 across all filing types
Latest filing 2023-05-12 Legal Proceedings Report
Country KR South Korea
Listing KO 004310

About HYUNDAI PHARMACEUTICAL CO., LTD

http://www.hyundaipharm.co.kr/english

HYUNDAI PHARMACEUTICAL CO., LTD. is a company engaged in the research, development, manufacturing, and distribution of pharmaceutical products, medical devices, and health-focused food and beverages. The company's portfolio encompasses a broad range of prescription (ETC) and over-the-counter (OTC) medicines. Key therapeutic areas include dermatology, respiratory and gastrointestinal disorders, as well as treatments for conditions such as hypertension and dementia. With a strong commitment to innovation, the company focuses on the research of new substances and the continuous development of its drug pipeline. It also serves as a strategic partner for global companies, facilitating market entry and collaboration through its business development initiatives.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure from Hyundai Pharm regarding the results of a Phase 3 clinical trial for an Alzheimer's treatment (BPDO-1603). It details the trial methodology, statistical analysis of the results (which failed to reach statistical significance), and future reporting plans. Since this is a specific regulatory announcement regarding material business developments (clinical trial results) that does not fit into financial reporting or other specific categories, it is classified as a Regulatory Filing (RNS).
2023-05-12 Korean
단기차입금증가결정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory announcement from Hyundai Pharm regarding a decision to increase short-term borrowings. It details the loan amount, the purpose (operating funds), and the board resolution date. This falls under corporate financing activities and capital structure changes, which is best categorized as CAP (Capital/Financing Update).
2023-05-11 Korean
분기보고서 (2023.02)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Hyundai Pharm Co., Ltd. covering the period from December 1, 2022, to February 28, 2023. It contains detailed financial information, business operations, management discussions, and capital structure data. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. Q1 2023
2023-04-14 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the voting outcomes from the meeting held on 2023-02-24. It covers the approval of financial statements, dividend declarations, election of directors and audit committee members, and remuneration limits. This aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2023-02-24 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment, dismissal, or resignation of an outside director (사외이사). This type of corporate governance disclosure specifically pertains to changes in the board of directors, which falls under the 'Board/Management Information' category.
2023-02-24 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing titled '감사보고서 제출' (Submission of Audit Report) by Hyundai Pharm. It provides a summary of the audit opinion (unqualified/appropriate) and key financial data (assets, liabilities, revenue, profit/loss) for the fiscal year ending 2022-11-30. While it contains financial data, it is a formal notification of the submission of the audit report to the regulatory body (KRX), rather than the full annual report or a standalone audit report document. According to the 'Menu vs Meal' rule, this is a notification of a report filing, which falls under the category of Report Publication Announcement (RPA). FY 2022
2023-02-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.